Aim: The ongoing COVID-19 pandemic is an acute medical, social, political and economic problem. Acute myocarditis is a rare complication of the widely used mRNA-based vaccines. Case Presentation: 20-year old male with...Aim: The ongoing COVID-19 pandemic is an acute medical, social, political and economic problem. Acute myocarditis is a rare complication of the widely used mRNA-based vaccines. Case Presentation: 20-year old male with no preexisting disease or cardiovascular risk factor presented in October 2021 with chest pain after receiving the second dose of the Moderna COVID-19 vaccine 2 days previously. He discharged from ward care only a few days after his initial presentation. Conclusion: Despite the meta-analysis results suggesting a higher risk of myocarditis with COVID-19 vaccination, vaccination should still be recommended because benefits of the vaccine likely outweigh its harms.展开更多
The CD4FOXP3regulatory T(Treg)cells are essential for maintaining immune homeostasis in healthy individuals.Results from clinical trials of Treg cell-based therapies in patients with graft versus host disease(GVHD),ty...The CD4FOXP3regulatory T(Treg)cells are essential for maintaining immune homeostasis in healthy individuals.Results from clinical trials of Treg cell-based therapies in patients with graft versus host disease(GVHD),type 1 diabetes(T1D),liver transplantation,and kidney transplantation have demonstrated that adoptive transfer of Treg cells is emerging as a promising strategy to promote immune tolerance.Here we provide an overview of recent progresses and current challenges of Treg cell-based therapies.We summarize the completed and ongoing clinical trials with human Treg cells.Notably,a few of the chimeric antigen receptor(CAR)-Treg cell therapies are currently undergoing clinical trials.Meanwhile,we describe the new strategies for engineering Treg cells used in preclinical studies.Finally,we envision that the use of novel synthetic receptors,metabolic regulators,combined therapies,and in vivo generated antigen-specific or engineered Treg cells through the delivery of modified mRNA and CRISPR-based gene editing will further promote the advances of next-generation Treg cell therapies.展开更多
文摘Aim: The ongoing COVID-19 pandemic is an acute medical, social, political and economic problem. Acute myocarditis is a rare complication of the widely used mRNA-based vaccines. Case Presentation: 20-year old male with no preexisting disease or cardiovascular risk factor presented in October 2021 with chest pain after receiving the second dose of the Moderna COVID-19 vaccine 2 days previously. He discharged from ward care only a few days after his initial presentation. Conclusion: Despite the meta-analysis results suggesting a higher risk of myocarditis with COVID-19 vaccination, vaccination should still be recommended because benefits of the vaccine likely outweigh its harms.
基金supported by National Science Foundation for Distinguished Young Scholars (31525008)National Natural Science Foundation of China (32130041, 81830051, 31961133011)+4 种基金The National Key Research and Development Project (2019YFA0906102)Shanghai Collaborative Innovation Center of Cellular Homeostasis Regulation and Human DiseasesShanghai Jiao Tong University (SJTU)-The Chinese University of Hong Kong (CUHK) Joint Research Collaboration Fundthe Fundamental Research Funds for Central UniversitiesInnovative research team of high-level local universities in Shanghai (SHSMU-ZDCX20210601)
文摘The CD4FOXP3regulatory T(Treg)cells are essential for maintaining immune homeostasis in healthy individuals.Results from clinical trials of Treg cell-based therapies in patients with graft versus host disease(GVHD),type 1 diabetes(T1D),liver transplantation,and kidney transplantation have demonstrated that adoptive transfer of Treg cells is emerging as a promising strategy to promote immune tolerance.Here we provide an overview of recent progresses and current challenges of Treg cell-based therapies.We summarize the completed and ongoing clinical trials with human Treg cells.Notably,a few of the chimeric antigen receptor(CAR)-Treg cell therapies are currently undergoing clinical trials.Meanwhile,we describe the new strategies for engineering Treg cells used in preclinical studies.Finally,we envision that the use of novel synthetic receptors,metabolic regulators,combined therapies,and in vivo generated antigen-specific or engineered Treg cells through the delivery of modified mRNA and CRISPR-based gene editing will further promote the advances of next-generation Treg cell therapies.
